한글목차

세계 간섬유증 및 NASH/MASH 치료제 시장 규모는 2025년 183억 달러로 추정되며, 예측 기간 동안 CAGR 10.0%로 성장할 것으로 예상됩니다.

NASH/MASH 치료제 승인에 대한 규제 과제와 시장 장벽:

NASH/MASH는 간섬유화, 간경변증으로 진행되어 보건 보건 위기를 가속화하고 있습니다. MASH는 주로 제 2형 당뇨병 및 심혈관질환과 관련이 있습니다. 임상시험에서 NASH 치료제는 간 관련 결과와 관련된 복합 평가변수를 측정하여 질병의 진행을 늦추거나 발병을 예방하는 능력을 입증할 것입니다.

그러나 현재 NASH에 대한 효과적인 치료법이 없기 때문에 미국 FDA는 다른 승인 경로를 마련했습니다. 이 경로는 간 생검을 통한 병리조직학적 병태생리학적 평가와 임상시험 중 양호한 임상 결과를 대체 평가지표로 삼고 있습니다. 그 결과, 미국 FDA는 MASH의 악화 없이 섬유화 a*1 단계의 개선 또는 섬유화 악화를 동반하지 않는 MASH의 소실 중 하나를 입증하여 주요 평가항목을 충족하는 약물을 승인하고 있습니다.

반면, 유럽의약품청(EMA)의 규제 요건은 미국 FDA와 다른데, EMA는 두 가지 주요 평가 항목을 모두 충족해야 하며, 섬유증 개선과 함께 NASH의 완전한 소실을 요구하고 있습니다. 전 세계적으로 통일된 임상시험 요건이 없다는 것은 제약사들에게 큰 도전이 되고 있습니다.

세계의 간섬유증 및 NASH/MASH 치료제 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별·주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• 규제 체계
• Porter's Five Forces 분석
• PEST 분석

제4장 간섬유증 치료제 시장 분석 : 질환 유형별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 항바이러스제
• 알코올성 간질환(ALD)
• 자가면역성 간질환
• 항산화제
• 약물로 인한 간 손상(DILI)
  • 시장 규모 추정과 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 NASH/MASH 치료제 시장 분석

• 주요 조사 결과
• 간섬유증/NASH//MASH 치료제 규모 : 시장 규모 예측
• 비타민 E와 피오글리타존
• 레즈디프라
• 세마글루타이드(오젬픽)
• 티르제파타이드
• 펨비두타이드
• 라니피브라노르
• 벨라펙틴
• 에프루시퍼민
• 페고사퍼민
• 드니판스타트
• 병용요법

제6장 NASH/MASH 치료제 시장의 파이프라인 의약품 분석

• 주요 조사 결과
• 2024년까지 다양한 임상시험 단계에 있는 NASH/MASH 파이프라인 수
• 단계 III 임상시험 : NASH/MASH 시장
• 단계 II 임상시험 : NASH/MASH 시장
• 파이프라인 병용요법 : NASH/MASH 시장
• 파이프라인 병용요법 : 간경변을 수반하는 NASH/MASH 시장
• 신규 참여자/신기술 임상시험 : NASH/MASH 시장
• 임상시험 : 약물 재이용 간섬유증 시장

제7장 NASH//MASH 치료제 시장 분석 : 주요 국가별

• 주요 조사 결과
• NASH/MASH 시장 : 섬유화 단계별(%)
• NASH/MASH 지역 분석 : 시장 점유율(%)
  • 시장 규모 : 지역별
• 미국
• 영국
• 프랑스
• 이탈리아
• 스페인
• 독일
• 일본
• 중국

제8장 간섬유증 치료제 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 병원 약국
• 전문 약국
• 기타 약국
  • 시장 규모 추정과 예측 : 지역별
  • 시장 점유율 : 지역별

제9장 간섬유증 및 NASH//MASH 치료제 시장 분석

• 주요 조사 결과
• 시장 규모 추정과 예측

제10장 북미의 간섬유증 시장 분석

제11장 유럽의 간섬유증 및 NASH/MASH 치료제 시장 분석

제12장 아시아태평양의 간섬유증 및 NASH/MASH 치료제 시장 분석

제13장 라틴아메리카의 간섬유증 및 NASH/MASH 치료제 시장 분석

제14장 중동 및 아프리카의 간섬유증 및 NASH/MASH 치료제 시장 분석

제15장 기업 개요

• 경쟁 구도
• Madrigal Pharmaceuticals
• Novo Nordisk.
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Inventiva Pharma
• Galectin Therapeutics
• Galmed Pharmaceutical
• Akero Therapeutics
• AstraZeneca plc
• .Altimmune
• Boehringer Ingelheim

제16장 결론과 제안

• Visiongain에 의한 결론
• 진출 기업에 대한 제안

영문목차

The global Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035 market is estimated at US$18.3 billion in 2025 and is projected to grow at a CAGR of 10.0% during the forecast period 2025-2035.

The Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Regulatory Challenges and Market Barriers in NASH/MASH Drug Approval

NASH/MASH is an escalating public health crisis, with the disease progressively leading to liver fibrosis and cirrhosis. MASH is primarily associated with type 2 diabetes and cardiovascular diseases. During clinical trials, NASH drugs must demonstrate their ability to delay disease progression and prevent its onset by measuring composite endpoints related to liver-associated outcomes.

However, due to the absence of effective treatments currently available for NASH, the U.S. FDA has provided an alternative approval pathway. This pathway relies on histopathological assessment of disease progression through liver biopsies as surrogate endpoints, along with positive clinical outcomes during trials. Consequently, the U.S. FDA approves drugs that meet the primary endpoints by either demonstrating an improvement of ,a*1 stage in fibrosis with no worsening of MASH or achieving MASH resolution without worsening fibrosis.

In contrast, the European Medicines Agency (EMA) has different regulatory requirements compared to the U.S. FDA. The EMA mandates that both primary endpoints be met, requiring complete resolution of NASH along with improvement in fibrosis. The lack of uniformity in clinical trial requirements at a global level poses a significant challenge for pharmaceutical companies.

Beyond meeting these endpoints, the effects of new therapies must also be evaluated for their impact on type 2 diabetes and cardiovascular risks. For complete regulatory approval, clinical outcomes should include mortality rates, cirrhosis progression reports, and other liver-related events. This necessitates long-term patient monitoring and follow-up during clinical trials, with the added risk of product failure in confirmatory trials. Additionally, patients receiving a placebo may be required to wait despite the drug being commercially available.

Thus, the lack of regulatory uniformity and the complexity of NASH as a disease hinder the timely commercialization of these drugs.

What Questions Should You Ask before Buying a Market Research Report?

• How is the Liver Fibrosis & NASH/MASH Drugs market evolving?
• What is driving and restraining the Liver Fibrosis & NASH/MASH Drugs market?
• How will each Liver Fibrosis & NASH/MASH Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each Liver Fibrosis & NASH/MASH Drugs submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading Liver Fibrosis & NASH/MASH Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Liver Fibrosis & NASH/MASH Drugs projects for these leading companies?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of
• Liver Fibrosis & NASH/MASH Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Liver Fibrosis & NASH/MASH Drugs market?
• Where is the Liver Fibrosis & NASH/MASH Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Liver Fibrosis & NASH/MASH Drugs market today, and over the next 10 years:

• Our 245-page report provides 112 tables, 138 charts exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them - NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2035 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

• Liver Fibrosis Disease Drug Type
• Antiviral
• Alcoholic Liver Disease
• Antioxidants
• Immunosuppressants
• Drug Induced Liver Injury
• NASH/MASH Market by Drugs by Type
• Vitamin E & Pioglitazone
• Rezdiffra
• Semaglutide
• Tirzepatide
• Pemvidutide
• Lanifibranor
• Belapectin
• Efruxifermin
• Pegozafermin
• Denifanstat
• Combination Therapies
• NASH/MASH Drugs by Clinical Pipeline
• Phase III
• Phase II
• New Entrants
• Combination Therapies
• Repurposing Drugs
• Liver Fibrosis Drugs Market by End Users
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles for some of the leading companies in the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035, with a focus on this segment of these companies' operations.

• Leading companies and the potential for market growth
• List of Companies Profiled in the Report
• Madrigal Pharmaceuticals
• Novo Nordisk
• Eli Lilly
• Gilead Sciences Inc.
• Galectin Therapeutics
• Galmed Pharmaceuticals
• Akero Therapeutics
• AstraZeneca plc
• Altimmune
• Boehringer Ingelheim

Overall world revenue for Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035 in terms of value the market will surpass US$18.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035 report help you?
• In summary, our 240+ page report provides you with the following knowledge:
• Revenue forecasts to 2035 for Liver Fibrosis & NASH/MASH Drugs Market 2025 to 2035, with forecasts for Type and Indication, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 20 key national markets - See forecasts for the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, South Korea and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035.
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Liver Fibrosis / NASH / MASH Drugs Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Rise in Prevalence of Liver Diseases
    • 3.3.1.2 Rise in diabetes and obesity pandemic consequently leading to rise in MASH
    • 3.3.1.3 Early diagnosis via adoption of Non-invasive diagnostics tests
    • 3.3.1.4 Growing adoption of Artificial Intelligence for Liver Disease Diagnosis
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 High Cost of Diagnosis & Drugs Limits the Growth of the Market
    • 3.3.2.2 Delayed Diagnosis of MASH & Fibrosis
    • 3.3.2.3 Regulatory Hurdles
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Diagnostic & Biopharma Partnerships
    • 3.3.3.2 Nano-Particle Based Drug Delivery
• 3.4 Regulatory Framework
• 3.5 Porter's Five Forces Analysis
  • 3.5.1 Bargaining Power of Suppliers
  • 3.5.2 Bargaining Power of Buyers
  • 3.5.3 Competitive Rivalry
  • 3.5.4 Threat of Substitutes
  • 3.5.5 Threat of New Entrants
• 3.6 PEST Analysis

4 Liver Fibrosis Drugs Market Analysis, by Disease Type

• 4.1 Key Findings
• 4.2 Product Type Segment: Market Attractiveness Index
• 4.3 Liver Fibrosis / NASH / MASH drugs market Size Estimation and Forecast by Drug Type
• 4.4 Antivirals
  • 4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 4.4.2 Market Share by Region, 2025 & 2035 (%)
• 4.5 Alcoholic Liver Disease (ALD)
  • 4.5.1 Market Size by Region, 2025-2035 (US$ Million)
  • 4.5.2 Market Share by Region, 2025 & 2035 (%)
• 4.6 Autoimmune Liver Disease
  • 4.6.1 Market Size by Region, 2025-2035 (US$ Million)
  • 4.6.2 Market Share by Region, 2025 & 2035 (%)
• 4.7 Anti-Oxidant Modulators
  • 4.7.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 4.7.2 Market Share by Region, 2025 & 2035 (%)
• 4.8 Drug Induced Liver Injury (DILI)
  • 4.8.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 4.8.2 Market Share by Region, 2025 & 2035 (%)

5 NASH / MASH Drugs Market Analysis

• 5.1 Key Findings
• 5.2 Liver Fibrosis / NASH / MASH Drugs Market Size Estimation and Forecast by Drugs
• 5.3 Vitamin E & Pioglitazone
• 5.4 Rezdiffra
• 5.5 Semaglutide (Ozempic)
• 5.6 Tirzepatide
• 5.7 Pemvidutide
• 5.8 Lanifibranor
• 5.9 Belapectin
• 5.10 Efruxifermin
• 5.11 Pegozafermin
• 5.12 Denifanstat
• 5.13 Combination Therapies

6 NASH / MASH Drugs Market Analysis by Pipeline Drugs

• 6.1 Key Findings
• 6.2 Number of NASH/MASH Pipeline in Various Clinical Trial Stage,2024
• 6.3 Phase III Clinical Trials : NASH/MASH Market
• 6.4 Phase II Clinical Trials : NASH/MASH Market
• 6.5 Pipeline Combination Therapies: NASH/MASH Market
• 6.6 Pipeline Combination Therapies: NASH/MASH Market with Cirrhosis
• 6.7 New Entrants / New Technology Clinical Trials : NASH/MASH Market
• 6.8 Clinical Trials : Repurposing Drugs Liver Fibrosis Market

7 NASH / MASH Drugs Market Analysis by Major Countries

• 7.1 Key Findings
• 7.2 NASH/MASH Market : By Stage of Fibrosis (%)
• 7.3 NASH/MASH Geographic Analysis : By Market Share (%)
  • 7.3.1 Market Size by Region, 2025-2035 (US$ Billion)
• 7.4 U.S.
• 7.5 UK
• 7.6 France
• 7.7 Italy
• 7.8 Spain
• 7.9 Germany
• 7.10 Japan
• 7.11 China

8 Liver Fibrosis Drugs Market Analysis by End-users

• 8.1 Key Findings
• 8.2 End-users Segment: Market Attractiveness Index
• 8.3 Liver Fibrosis drugs market Size Estimation and Forecast by End-users
• 8.4 Hospital Pharmacies
  • 8.4.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 8.4.2 Market Share by Region, 2025 & 2035 (%)
• 8.5 Speciality Pharmacies
  • 8.5.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 8.5.2 Market Share by Region, 2025 & 2035 (%)
• 8.6 Other Pharmacies
  • 8.6.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 8.6.2 Market Share by Region, 2025 & 2035 (%)

9 Liver Fibrosis / NASH / MASH Drugs Market Analysis by Region

• 9.1 Key Findings
• 9.2 Regional Market Size Estimation and Forecast

10 North America Liver Fibrosis Market Analysis

• 10.1 Key Findings
• 10.2 North America Liver fibrosis Drugs market Attractiveness Index
• 10.3 North America Liver Fibrosis Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 North America Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
• 10.5 North America Liver Fibrosis Drugs Market Size Estimation and Forecast by Indications
• 10.6 North America Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
• 10.7 U.S. Liver Fibrosis Drugs Market Analysis
• 10.8 Canada Liver Fibrosis Drugs market Analysis

11 Europe Liver Fibrosis / NASH / MASH Drugs Market Analysis

• 11.1 Key Findings
• 11.2 Europe Liver Fibrosis Drugs Market Attractiveness Index
• 11.3 Europe Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 11.4 Europe Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
• 11.5 Europe Liver Fibrosis drugs market Size Estimation and Forecast by Indications
• 11.6 Europe Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
• 11.7 Germany Liver fibrosis Drugs market Analysis
• 11.8 France Liver fibrosis Drugs market Analysis
• 11.9 UK Liver fibrosis Drugs market Analysis
• 11.10 Italy Liver fibrosis Drugs market Analysis
• 11.11 Spain Liver fibrosis Drugs market Analysis
• 11.12 Russia Liver Fibrosis Drugs Market Analysis
• 11.13 Rest of Europe Liver Fibrosis Drugs Market Analysis

12 Asia Pacific Liver Fibrosis Drugs Market Analysis

• 12.1 Key Findings
• 12.2 Asia Pacific Liver Fibrosis drugs market Attractiveness Index
• 12.3 Asia Pacific Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 12.4 Asia Pacific Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
• 12.5 Asia-Pacific Liver Fibrosis drugs market Size Estimation and Forecast by Indications
• 12.6 Asia-Pacific Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
• 12.7 Japan Liver fibrosis Drugs market Analysis
• 12.8 China Liver fibrosis Drugs market Analysis
• 12.9 India Liver fibrosis Drugs market Analysis
• 12.10 Australia Liver Fibrosis Drugs Market Analysis
• 12.11 South Korea Liver Fibrosis Drugs Market Analysis
• 12.12 Rest of Asia-Pacific Liver fibrosis Drugs market Analysis

13 Latin America Liver Fibrosis Drugs Market Analysis

• 13.1 Key Findings
• 13.2 Latin America Liver Fibrosis Drugs Market Attractiveness Index
• 13.3 Latin America Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 13.4 Latin America Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
• 13.5 Latin America Liver Fibrosis drugs market Size Estimation and Forecast by Indications
• 13.6 Latin America Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
• 13.7 Brazil Liver Fibrosis Drugs Market Analysis
• 13.8 Mexico Liver fibrosis Drugs market Analysis
• 13.9 Rest of Latin America Fibrosis Drugs market Analysis

14 MEA Liver fibrosis Drugs Market Analysis

• 14.1 Key Findings
• 14.2 MEA Liver Fibrosis Drugs Market Attractiveness Index
• 14.3 MEA Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 14.4 MEA Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
• 14.5 MEA Liver Fibrosis Drugs market Size Estimation and Forecast by Indications
• 14.6 MEA Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
• 14.7 GCC Liver Fibrosis drugs market Analysis
• 14.8 South Africa Liver Fibrosis Drugs Market Analysis
• 14.9 Rest of MEA Fibrosis Drugs Market Analysis

15 Company Profiles

• 15.1 Competitive Landscape, 2024
• 15.2 Madrigal Pharmaceuticals
  • 15.2.1 Company Snapshot
  • 15.2.2 Company Overview
  • 15.2.3 Product Benchmarking
  • 15.2.4 SWOT Analysis
  • 15.2.5 Strategic Outlook
• 15.3 Novo Nordisk.
  • 15.3.1 Company Snapshot
  • 15.3.2 Company Overview
  • 15.3.3 Financial Analysis
    • 15.3.3.1 Net Revenue, 2019-2023
    • 15.3.3.2 Regional Market Share, 2023 (%)
  • 15.3.4 Product Benchmarking
  • 15.3.5 SWOT Analysis
  • 15.3.6 Pipeline Analysis
  • 15.3.7 Strategic Outlook
• 15.4 Eli Lilly and Company
  • 15.4.1 Company Snapshot
  • 15.4.2 Company Overview
  • 15.4.3 Financial Analysis
    • 15.4.3.1 Net Revenue, 2019-2023
    • 15.4.3.2 R&D, 2019-2023
    • 15.4.3.3 Regional Market Share, 2023 (%)
  • 15.4.4 Pipeline Analysis
  • 15.4.5 Strategic Outlook
  • 15.4.6 SWOT Analysis
• 15.5 Gilead Sciences, Inc.
  • 15.5.1 Company Snapshot
  • 15.5.2 Company Overview
  • 15.5.3 Financial Analysis
    • 15.5.3.1 Net Revenue, 2018-2023
    • 15.5.3.2 R&D, 2018-2023
    • 15.5.3.3 Regional Market Shares, 2023
    • 15.5.3.4 Business Segment Market Shares, 2023
  • 15.5.4 Product Benchmarking
  • 15.5.5 Strategic Outlook
• 15.6 Inventiva Pharma
  • 15.6.1 Company Snapshot
  • 15.6.2 Company Overview
  • 15.6.3 Financial Analysis
    • 15.6.3.1 Net Revenue, 2018-2023
  • 15.6.4 Product Benchmarking
• 15.7 Galectin Therapeutics
  • 15.7.1 Company Snapshot
  • 15.7.2 Company Overview
  • 15.7.3 Financial Analysis
  • 15.7.4 Product Benchmarking
  • 15.7.5 Pipeline Analysis
  • 15.7.6 Strategic Outlook
• 15.8 Galmed Pharmaceutical
  • 15.8.1 Company Snapshot
  • 15.8.2 Company Overview
  • 15.8.3 Financial Analysis
  • 15.8.4 Product Benchmarking
  • 15.8.5 Pipeline Analysis
  • 15.8.6 Strategic Outlook
• 15.9 Akero Therapeutics
  • 15.9.1 Company Snapshot
  • 15.9.2 Company Overview
  • 15.9.3 Financial Analysis
  • 15.9.4 Product Benchmarking
  • 15.9.5 Pipeline Analysis
  • 15.9.6 Strategic Outlook
• 15.10 AstraZeneca plc
  • 15.10.1 Company Snapshot
  • 15.10.2 Company Overview
  • 15.10.3 Financial Analysis
    • 15.10.3.1 Net Revenue, 2017-2023
    • 15.10.3.2 R&D, 2017-2023
    • 15.10.3.3 Regional Market Shares, 2023
    • 15.10.3.4 Business Segment Market Shares, 2023
  • 15.10.4 Pipeline Analysis
• 15.11 .Altimmune
  • 15.11.1 Company Snapshot
  • 15.11.2 Company Overview
  • 15.11.3 Pipeline Analysis
  • 15.11.4 Strategic Outlook
• 15.12 Boehringer Ingelheim
  • 15.12.1 Company Snapshot
  • 15.12.2 Company Overview
    • 15.12.2.1 Net Revenue, 2019-2023
    • 15.12.2.2 R&D, 2019-2023
    • 15.12.2.3 Regional Market Shares, 2023
    • 15.12.2.4 Business Segment Market Shares, 2023
  • 15.12.3 Pipeline Analysis
  • 15.12.4 Strategic Outlook

16 Conclusion and Recommendations

• 16.1 Concluding Remarks from Visiongain
• 16.2 Recommendations for Market Players